Sanjay Ahuja Appointed CEO and Medical Director of Innovative Hematology
Sanjay Ahuja, Chief Medical Officer, CEO and Medical Director of Innovative Hematology, Inc., shared Innovative Hematology, Inc.‘s post on LinkedIn:
“I am deeply grateful for this opportunity, and both honored and humbled by the responsibility it carries.
As I reflect on this moment, I’m reminded that none of us walks this path alone. We stand on the shoulders of those who came before us, lean on those who walk alongside us, and have a responsibility to lift those who follow.
Thankful for the mentors, colleagues, and teams who have made this journey possible
As I look ahead, I’m inspired by the opportunity to build, to serve, and to create something that meaningfully improves the lives of our patients we are so privileged to serve.
The work continues—and the best is still ahead.”
Innovative Hematology, Inc. shared a post on LinkedIn:
“Today marks Dr. Sanjay Ahuja‘s first day as Medical Director and CEO of Innovative Hematology.
As we look ahead, our focus now is clear:
to build on the strong foundation already in place, strengthen the continuity of care our patients depend on, and position IHI for thoughtful and sustainable growth.
Stay updated with Hemostasis Today.
-
Nov 15, 2026, 16:29Jean-Jacques Kiladjian: 20 Years of Interferon-Alpha Research in Myeloproliferative Neoplasms
-
Nov 15, 2026, 16:21Sukanto Paul: Why Platelet Transfusion Is Generally Avoided in TTP
-
Nov 15, 2026, 16:14Ahmad G. Alzahrani: Major Bleeding and Anticoagulant Reversal
-
Nov 15, 2026, 16:05Sabine Eichinger: Is Recurrence Risk After Provoked VTE Really Low?
-
Nov 15, 2026, 15:53Nicolas Schommer: The Seed and Soil Hypothesis of NET-Mediated Inflammation
-
Nov 15, 2026, 15:36Giovanni Merlino: Targeting LDL-C to Prevent Recurrent Stroke
-
Nov 15, 2026, 15:33Riitta Lassila: From Helsinki to ISTH 2027 Advancing Thrombosis Research
-
Nov 15, 2026, 15:30Andreas Calatzis: Can Protein C and Plasma Overcome Fibrinolysis Resistance in Sepsis?
-
Nov 15, 2026, 15:25Hussnain Javaid: Thalassaemia 2026 New Therapies Transforming UK Practice